表紙
市場調査レポート

医薬品受託製造:世界の産業および市場の展望 (2016-2026年)

Pharmaceutical Contract Manufacturing 2016-2026: Discover Revenue Forecasts for Active Ingredient (API) and Finished Dose Formulation (FDF) Services

発行 Visiongain Ltd 商品コード 214197
出版日 ページ情報 英文 237 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1GBP=141.53円で換算しております。

ご注意:
Single UserとDepartmentalライセンスは、DRM (デジタル著作権管理システム) 付PDFになります。
制限内容は、上記ライセンスの[?]アイコンをクリックしてご確認ください。

Back to Top
医薬品受託製造:世界の産業および市場の展望 (2016-2026年) Pharmaceutical Contract Manufacturing 2016-2026: Discover Revenue Forecasts for Active Ingredient (API) and Finished Dose Formulation (FDF) Services
出版日: 2016年03月08日 ページ情報: 英文 237 Pages
概要

世界の医薬品受託製造の市場は2020年には839億ドルの規模に成長すると予測されており、2016年から2026年にかけて大幅な収益拡大が見込まれ、企業にとっては大きなビジネスチャンスが期待できます。

当レポートでは、世界の医薬品受託製造の産業および市場について調査し、医薬品受託製造の概要、受託製造の理由・メリット、受託製造機関 (CMO) による提供サービス、主要なCMO、市場全体および製造対象 (API・FDF)・詳細区分別の市場規模の推移と予測、先進国市場および新興国市場の動向、CMOおよびクライアントの視点による市場の展望などについてまとめています。

第1章 レポート概要

第2章 医薬品受託製造:イントロダクション

  • 医薬品受託製造とは
  • 医薬品市場におけるアウトソースのメリット
  • CMOによる提供サービス
  • 戦術的・戦略的アウトソーシング
  • 医薬品受託製造の動向・展望
  • 市場区分

第3章 医薬品受託製造市場の予測

  • 医薬品受託製造:市場の実績
  • 医薬品受託製造:全体市場の予測

第4章 API (医薬原体) 受託製造市場の展望

  • API受託製造の市場:市場実績
  • API受託製造の市場:市場予測
  • ジェネリックAPI受託製造の市場:市場予測
  • HPAPI (高活性医薬原体) 受託製造の市場:市場予測

第5章 FDF (最終製剤) 受託製造市場の展望

  • FDF受託製造の市場:市場実績
  • FDF受託製造の市場:市場予測
  • 固体製剤受託製造の市場:市場予測
  • 注射用製剤受託製造の市場:市場予測

第6章 医薬品受託製造:主要先進国市場の予測

  • 医薬品受託製造の主要国市場
  • 米国市場の予測
  • EUにおける医薬品受託製造の見通し
  • 日本における医薬品受託製造の見通し

第7章 医薬品受託製造:主要新興国市場の予測

  • 新興国における医薬品受託製造
  • 中国の医薬品受託製造サービス需要の見通し
  • インド:強いインフラ基盤を持ち、製剤経験を重ねるCMOの存在
  • ブラジル:受託製造の展望
  • ロシアの医薬品受託製造市場の予測
  • 韓国:政府の支援により成長

第8章 医薬品受託製造市場における主要企業

  • 主な受託製造機関 (CMO)
  • Catalent:市場のリーダー
  • Lonza:ADC製造をリードする可能性
  • Evonik Degussa:小分子の専門企業
  • DPx Holdings - DSM and Patheon:最近の合併で地位強化
  • Teva API:世界最大のAPI製造業者
  • Boehringer Ingelheim BioXcellence:Boehringerのバイオ医薬製造部門
  • Famar:有力な買収候補
  • Fareva:買収から容量増加へ戦略変更
  • Vetter Pharma:無菌充填、凍結乾燥およびシリコン処理のスペシャリスト
  • Mylan:ジェネリック医薬品製造の世界的リーダー

第9章 医薬品受託製造産業の動向:CMOの展望

  • 強み・弱み
  • 機会・脅威
  • STEP分析
  • CMOに影響を及ぼす創薬の動向
  • 今後の10年におけるCMOの拡大
  • 製造工程における発展

第10章 医薬品受託製造産業の動向:クライアントの展望

  • 強み・弱み
  • 機会・脅威
  • アウトソーシングの意思決定における重要側面
  • アウトソーシング提携の動向

第11章 専門家へのインタビュー

第12章 総論

  • 世界の医薬品受託製造市場
  • 市場の展望
  • 需要を刺激する新技術

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: PHA0097

Contract drug production - discover trends and markets with highest revenue potentials

Where is outsourced pharma manufacturing heading? Visiongain's updated study predicts that industry's revenues from 2016. There you find potentials for sales growth, also exploring trends, technologies, clients' needs and opportunities.

That new report gives you revenue forecasts to 2026 at overall world market, submarket and national level. Avoid falling behind in data. Instead see what is happening for those medical contracting services - outsourcing and off-shoring - hearing how you can gain and benefit your influence.

Please read on to explore that industry and discover what revenue its future market could generate.

Forecasts to 2026 and other analysis show you commercial prospects

From 2016, pharma contract manufacturing organisations (CMOs) hold great potential for small-molecule drugs and biologicals. See what sales expansion is possible.

Besides revenue forecasting to 2026, our new study shows you historical data, growth rates and market shares. See developments in technology and service offerings, finding their meaning. And in our updated report you get 79 tables, 59 charts and interviews with two companies.

With our study you assess trends, demands and sales potentials in the pharma contract and custom manufacturing industry. You see, from 2016, where needs and money exist. Discover the most lucrative pharmaceutical production services, including active compounds and complex drugs.

Gains through understanding those outsourcing services - advantages for your work

Avoid struggles to find that business data. Now you can stay ahead in knowledge for contracted drug making, benefiting your research, analysis and decisions. Finding information you need for producing medicines just became quicker and easier.

The following sections explain how you benefit from our new investigation.

Outsourced drug producing - forecasts from 2016 for the world market and submarkets

What are the secrets of that industry's progress? See expected trends there. Along with prediction of the overall world market for outsourced drug production, our report shows you revenue forecasting of 9 submarkets to 2026 at world level:

  • Active pharmaceutical ingredients (APIs), with sub forecasts for generic APIs, high potency active pharma ingredients (HPAPIs) and other products
  • Finished dosage formulations (FDFs), with sub forecasts for solid dose forms, injectable dosages and other dosage types
  • Other applications of outsourced production - other related services.

Our analyses and discussions show you commercial potentials for manufacturing service providers and their technologies. Discover those opportunities for improved production and revenue gains.

With our study you get the forecasting leaders need, benefiting your authority. Our study helps you stay ahead and succeed.

You get geographical revenue predictions, too, finding the best international prospects.

National and regional markets - what outlooks for demand, services and sales?

In developed and developing countries, opportunities for pharmaceutical CMOs will occur from 2016, leading to revenue gains. Find the most promising markets.

Our analyses give individual revenue forecasts to 2026 for 12 countries:

  • United States (US)
  • Germany, France, the UK, Italy and Spain - EU5 group, also with a regional prediction for the European Union
  • Brazil, Russia, India and China - BRIC countries
  • South Korea
  • Japan.

There you explore progress and outlooks. You assess that drug production sector's future - hear about developments, also finding their meaning and potential.

That way you find opportunity and assess challenges. Our work explains what the future holds, exploring issues affecting those drug production companies.

Forces affecting pharma CMOs and their clients

Our report shows you activities, developments and events affecting that industry and market from 2016, including these influences:

  • Trends for technology and business in biopharma manufacturing
  • US and EU regulations, as well as requirements in other countries
  • Generic Drug User Fee Act and API producing
  • GMP standards, quality by design (QbD) and virtual pharma companies
  • Potential for microreactors in outsourced drug making
  • Backwards integration for generics producers.

Visiongain's analysis also discusses other trends and needs, including these:

  • Investment in HPAPI manufacturing facilities
  • Complex-molecule production, esp. biologics (inc. biosimilars) and orphan medicines
  • Green technology in contract pharmaceuticals production
  • Aseptic filling for biological drugs and small-molecule medicines
  • Production of antibody-drug conjugates (ADCs) and other novel proteins
  • Lyophilisation, spray drying, hot-melt extrusion and fill-finish services.

With our survey you explore political, economic, social and technological questions, assessing outlooks for business. You examine forces stimulating and restraining that healthcare services industry.

You also see regulatory developments. Discover what that industry's present and future hold, exploring issues for contract drug makers and clients.

Leading companies and overall 2020 market value - how high can sales go?

What is possible for that industry? Our analysis predicts the world market for contract pharma manufacturing will reach $83.9bn in 2020. It will show strong revenue expansion from 2016 to 2026, giving companies high commercial potentials.

In particular our study explores activities, capabilities and results of these companies:

  • Catalent
  • Lonza
  • Evonik Degussa
  • DPx Holdings
  • Teva
  • Boehringer Ingelheim BioXcellence
  • Famar
  • Fareva
  • Vetter Pharma
  • Mylan.

There you analyse participants' results, strengths and outlooks. You also gain two interviews with other authorities, our discussions with Lonza and CordenPharma.

So discover what companies in that industry do and say, helping you stay ahead in knowledge and succeed.

7 Main Ways Pharmaceutical Contract Manufacturing 2016-2026 helps - gain data found nowhere else

Our new investigation helps you in these seven main ways, benefiting your research, plans, decisions and presentations:

  • Revenues to 2026 for outsourced drug production at overall world level - explore prospects for technologies, investments, sales and contracts
  • Prospects of 9 service submarkets - discover the revenue generating potentials of services that custom pharma manufacturing organisations offer
  • Forecasts to 2026 for 12 national markets in the Americas, Europe and Asia - investigate developed and developing countries' potentials
  • Outlooks for established and rising contract drug producers - assess portfolios, results, deals and outlooks, also with 10 company profiles
  • Clients' needs - explore production requirements of drug companies, assessing opportunities in serving drug developers, producers and marketers
  • Analysis of what stimulates and restrains the contract drug production market - explore that industry's trends, helping you compete and succeed
  • Interviews with companies and other industry news - discover what that industry's participants think, say and do, helping you stay ahead.

That report, by our in-house analysts in the UK, benefits your reputation for knowledge, helping you succeed. Gain analysis leading companies depend on.

Data found nowhere else, helping your research, assessments and planning

Our new investigation gives you independent analysis. You receive business intelligence found only in our work. With that study you are less likely to fall behind in data or miss opportunity. Instead discover what the future holds for your business.

That way discover where prospects and money exist. Our report's purpose is to benefit your research, analysis and decisions, also saving you time and effort.

Outsourced manufacturing of pharmaceuticals - explore that industry's future

Our new study is for everyone investigating production of small-molecule medicines and biological drugs. There you find revenue forecasting from 2016, seeing trends, developments and discussions. Avoid missing out - please get our report here now.

visiongain is a trading partner with the US Federal Government.

Table of Contents

1. Report Overview

  • 1.1. Global Pharmaceutical Contract Manufacturing Market Segmentation
  • 1.2. Global Pharmaceutical Contract Manufacturing Market Overview
  • 1.3. Why You Should Read This Report
  • 1.4. How This Report Delivers
  • 1.5. Key Questions Answered by This Analytical Report
  • 1.6. Who is This Report For?
  • 1.7. Methodology
  • 1.8. Frequently Asked Questions (FAQ)
  • 1.9. Associated Visiongain Reports
  • 1.10. About Visiongain

2. Introduction to Pharmaceutical Contract Manufacturing

  • 2.1. What is Pharmaceutical Contract Manufacturing?
  • 2.2. The Benefits of Outsourcing in the Pharmaceutical Market
  • 2.3. Pharmaceutical Contract Manufacturing Services
  • 2.4. Strategy and Tactics: The Importance of Outsourcing Wisely
  • 2.5. Trends in Contract Manufacturing, 2016-2026
  • 2.6. Pharmaceutical Contract Manufacturing: Market Segmentation

3. Pharmaceutical Contract Manufacturing: World Market 2015-2026

  • 3.1. Pharmaceutical Contract Manufacturing Market: Historical Performance 2012-2014
    • 3.1.1. Contract Manufacturing is the Most Mature Pharma Outsourcing Sector
    • 3.1.2. The Pharma Contract Manufacturing Market by Sector 2014
  • 3.2. Pharma Contract Manufacturing: Overall Market Forecast 2015-2026
    • 3.2.1. Changing Submarket Shares by Segment 2015-2026
    • 3.2.2. Drivers for Growth in the Contract Manufacturing Market to 2026
    • 3.2.3. Generics: A Driver or Restraint?
    • 3.2.4. Other Contract Manufacturing Services Submarket: Outlook and Forecast 2014-2016
      • 3.2.4.1. Increasing Demand for Formulation Development Services

4. The Contract API Manufacturing Services Submarket 2015-2026

  • 4.1. The Contract API Manufacturing Submarket 2014
    • 4.1.1. Chemical APIs Will Experience Resurgence After the Shift of Focus to Biological APIs
    • 4.1.2. The API Manufacturing Submarket by Sector 2014
  • 4.2. The Contract API Manufacturing Submarket: Outlook and Forecast 2015-2026
    • 4.2.1. Drivers for Growth in the API Submarket to 2026
    • 4.2.2. The Potential for Microreactors in Commercial Manufacturing to 2026
    • 4.2.3. How Will New EU Regulations Impact the API Manufacturing Submarket?
    • 4.2.4. Contract API Manufacturing Submarket Restraint 2016-2026
      • 4.2.4.1. Backwards Integration for Generics Manufacturers
  • 4.3. The Contract Generic API Manufacturing Submarket 2015-2026
    • 4.3.1. The Contract Generic API Manufacturing Submarket Forecast 2015-2026
    • 4.3.2. The Contract Generic API Manufacturing Submarket Drivers and Restraints to 2026
      • 4.3.2.1. The US Generic Drug User Fee Act and API Manufacturing
  • 4.4. The Contract HPAPI Manufacturing Submarket 2015-2026
    • 4.4.1. Challenges and Opportunities in High Containment Manufacturing
    • 4.4.2. Company Investment into HPAPI Manufacturing Facilities: Growth Increases in the HPAPI Manufacturing Sector
    • 4.4.3. The Contract HPAPI Manufacturing Submarket Forecast 2015-2026
    • 4.4.4. The Contract HPAPI Manufacturing Submarket Drivers and Restraints to 2026

5. The Contract FDF Manufacturing Services Submarket 2015-2026

  • 5.1. The Contract FDF Manufacturing Submarket 2014
    • 5.1.1. Solid Dosage Manufacturing Leads the Market
    • 5.1.2. CMOs Report High Demand for Softgel Formulations
  • 5.2. The Contract FDF Manufacturing Submarket Forecast 2015-2026
    • 5.2.1. Complex Molecule Manufacturing Will Drive Growth to 2026
    • 5.2.2. What Will Restrain Growth in FDF Outsourcing?
  • 5.3. The Contract Solid Dosage Manufacturing Submarket 2015-2026
    • 5.3.1. How Will Revenue for Solid Dosage Manufacturing Grow to 2026?
    • 5.3.2. The Solid Dosage Manufacturing Submarket Drivers and Restraints 2016-2026
      • 5.3.2.1. Will Product Reformulation Drive Growth to 2026?
  • 5.4. The Contract Injectable Dosage Manufacturing Submarket 2015-2026
    • 5.4.1. The Contract Injectable Dosage Manufacturing Submarket Forecast 2015-2026
      • 5.4.1.1. Drug Shortages Offer Opportunity to CMOs in the Short-Term
    • 5.4.2. Demand for Biopharma Manufacturing Will Drive Growth 2016-2026
      • 5.4.2.1. Interest in Antibody-Drug Conjugate Development Is Growing
      • 5.4.2.2. Challenges in Manufacturing Antibody-Drug Conjugates
    • 5.4.3. Lyophilisation and Aseptic Filling Demand Will Rise
      • 5.4.3.1. Will Spray Drying Replace Lyophilisation in FDF Manufacturing?

6. Leading National Markets for Pharmaceutical Contract Manufacturing 2015-2026

  • 6.1. Leading National Markets for Pharmaceutical Contract Manufacturing 2014
    • 6.1.1. Challenges in Assessing the Market: Supply versus Demand
    • 6.1.2. Leading National Pharmaceutical Contract Manufacturing Markets: Revenue Forecasts 2015-2026
    • 6.1.3. Pharmaceutical Manufacturing in the US: Regulatory Oversight 2014
    • 6.1.4. Controlling Foreign Manufacturing Sites
    • 6.1.5. What Impact Will the GDUFA 2012 Have on Foreign Manufacturing?
    • 6.1.6. Outsourcing and US Manufacturing Regulations
    • 6.1.7. Increased Demand for Domestic API Manufacturing?
  • 6.2. The US Contract Manufacturing Market Forecast 2015-2026
  • 6.3. Outlook for Pharmaceutical Contract Manufacturing in the EU
    • 6.3.1. The EU is the Leading Destination for Pharmaceutical Contract Manufacturing
    • 6.3.2. Regulatory Aspects of Pharma Manufacturing in the EU
      • 6.3.2.1. The European Commission Amends Annex 16
      • 6.3.2.2. The Falsified Medicine Directive: Controlling API Imports
    • 6.3.3. Biopharma Manufacturing Demand Will Rise to 2026
    • 6.3.4. The EU Contract Manufacturing Market Forecast 2015-2026
    • 6.3.5. Germany: The Leading EU Destination for API and FDF Manufacturing
      • 6.3.5.1. Demand for Contract Manufacturing in Germany: Revenue Forecast 2015-2026
    • 6.3.6. CMOs Account for a Third of Manufacturing Sites in France
      • 6.3.6.1. French Pharma Contract Manufacturing Market Forecast 2015-2026
    • 6.3.7. Italy: Strong API Manufacturing Traditions
      • 6.3.7.1. Revenue Forecast for the Italian Pharma Contract Manufacturing Market 2015-2026
    • 6.3.8. Spain: How Will Demand for Manufacturing Services Grow to 2026?
    • 6.3.9. UK: Pharmaceutical Contract Manufacturing Market Forecast 2015-2026
  • 6.4. Pharma Contract Manufacturing in Japan to 2026
    • 6.4.1. Pharmaceutical Manufacturing Regulations in Japan
      • 6.4.1.1. The Pharmaceutical Affairs Law
    • 6.4.2. Greater API Outsourcing to Drive Japanese Market Growth to 2026 In Spite of Currency Devaluation Weakening the Economy

7. Leading Emerging Markets for Pharmaceutical Contract Manufacturing 2015-2026

  • 7.1. Pharmaceutical Contract Manufacturing in Developing Countries
    • 7.1.1. Outsourcing to Emerging National Markets from Developed Markets
      • 7.1.1.1. Demand Will Increase for Services in India and China
    • 7.1.2. Domestic Demand for Pharmaceutical Contract Manufacturing Services
    • 7.1.3. Pharmaceutical Contract Manufacturing: Leading Emerging National Market Forecasts 2015-2026
  • 7.2. Chinese Demand for Pharma Contract Manufacturing Services 2015-2026
    • 7.2.1. Improved Manufacturing Regulations in China
      • 7.2.1.1. New Regulations for Excipients and Guidance for API Manufacturing 2012-2013
      • 7.2.1.2. What Are the Consequences to Stricter Manufacturing Regulations in China?
    • 7.2.2. Chinese CMOs Are Investing in Biopharma Manufacturing
    • 7.2.3. China Pharma Contract Manufacturing Market Forecast 2015-2026
  • 7.3. India: CMOs with Strong Infrastructure and Growing Expertise
    • 7.3.1. Regulatory Outlook for Indian Pharma Manufacturing
      • 7.3.1.1. Stricter Quality Standards to Ensure Compliance with EU Rules
    • 7.3.2. Domestic Manufacturing Dominates the Indian Pharma Market
    • 7.3.3. Demand for Contract Manufacturing in India: Market Forecast 2015-2026
  • 7.4. Brazil: Contract Manufacturing Outlook 2015-2026
    • 7.4.1. Pharmaceutical Manufacturing Regulations in Brazil
      • 7.4.1.1. New Guidelines and Regulations Proposed 2012-2013
    • 7.4.2. Brazil Imports Most of its APIs
    • 7.4.3. Brazil: Pharma Contract Manufacturing Market Forecast 2015-2026
  • 7.5. The Russian Pharma Contract Manufacturing Market 2015-2026
    • 7.5.1. Pharma Manufacturing Regulations in Russia
      • 7.5.1.1. Compliance with GMP in Russia
    • 7.5.2. How Will Demand for Contract Manufacturing Grow in Russia to 2026?
  • 7.6. South Korea: Government Supported Growth
    • 7.6.1. South Korea: Strict GMP Regulations
    • 7.6.2. South Korea: Pharma Contract Manufacturing Market Forecast 2015-2026

8. Leading Companies in the Pharmaceutical Contract Manufacturing Market

  • 8.1. Leading CMOs in the Pharmaceutical Contract Manufacturing Market
  • 8.2. Catalent: Leading CMO
    • 8.2.1. Multiple Expansions and Increased Focus on Biologic Manufacturing
  • 8.3. Lonza: Potential to Lead in ADC Manufacturing
    • 8.3.1. Lonza: Expanding its Capacities to Meet Customer Demand for Biologic Manufacturing
  • 8.4. Evonik Degussa: Specialising in Small Molecules
    • 8.4.1. Developments at Evonik Degussa
  • 8.5. DPx Holdings - DSM and Patheon: Recent Merger Has Strengthened Their Position
    • 8.5.1. Increasing Capacity Tactically and Expanding Worldwide
  • 8.6. Teva: The World's Largest API Manufacturer
    • 8.6.1. Will Teva Expand into Emerging Markets?
  • 8.7. Boehringer Ingelheim BioXcellence: Boehringer's Biopharma Manufacturing Division
    • 8.7.1. Adding New Services for Growth
  • 8.8. Famar: A Possible Candidate for Acquisition
  • 8.9. Fareva: A Strategic Shift from Acquisition to Increase in Capacity
  • 8.10. Vetter Pharma: Specialists in Aseptic Filling, Lyophilisation and Siliconisation
    • 8.10.1. Vetter's Growth: Increasing in Capacity and Market Expansion
  • 8.11. Mylan: A World Leader in Generics Manufacturing

9. Pharmaceutical Contract Manufacturing Industry Trends: Qualitative Analysis from a CMO Perspective 2016-2026

  • 9.1. Pharma Contract Manufacturing Market: Strengths and Weaknesses from a CMO Perspective 2016-2026
  • 9.2. Pharma Contract Manufacturing Market: Opportunities and Threats from a CMO Perspective 2016-2026
  • 9.3. Pharma Contract Manufacturing Market: STEP Analysis 2016-2026
    • 9.3.1. Social Factors
    • 9.3.2. New Technologies Will Drive Market Growth to 2026
      • 9.3.2.1. Advantages of Single-Use Technologies in Biopharma Manufacturing
      • 9.3.2.2. Green Technology in Contract Manufacturing
      • 9.3.2.3. Drug Delivery Trends and CMOs
      • 9.3.2.4. Biologics Are Causing Increased Demand for Lyophilisation
      • 9.3.2.5. Improving Solubility and Stability for Small Molecules
      • 9.3.2.6. Spray Drying as an Advantageous Alternative to Lyophilisation
      • 9.3.2.7. Hot-Melt Extrusion: A Niche Opportunity
    • 9.3.3. Economic Pressures
      • 9.3.3.1. Developed-Market CMOs Facing Competition from Emerging Markets
    • 9.3.4. Political Issues
      • 9.3.4.1. How Will Regulatory Developments Affect CMOs?
  • 9.4. Trends in Drug Development Affecting CMOs to 2026
    • 9.4.1. Orphan Drug Development: Smaller Manufacturing Capacities
    • 9.4.2. Complex Biologics: Interest in ADCs is Increasing
    • 9.4.3. How Will Biosimilar Market Growth Affect CMOs?
    • 9.4.4. The Future of Small Molecule Outsourcing
  • 9.5. How Will CMOs Expand in the Coming 10 Years?
    • 9.5.1. CMO Consolidation Will Increase
    • 9.5.2. There Will Be More Manufacturing Facilities Available for Acquisition
  • 9.6. Developments in the Manufacturing Process 2016-2026
    • 9.6.1. Rising Interest from Companies in Quality by Design (QbD)
    • 9.6.2. A Move Towards Continuous Manufacturing

10. Pharmaceutical Contract Manufacturing Trends: Qualitative Analysis of the Pharmaceutical Contract Manufacturing Market from a Client Perspective 2016-2026

  • 10.1. Pharma Contract Manufacturing Market: Strengths and Weaknesses from a Client Perspective 2016-2026
  • 10.2. Pharma Contract Manufacturing Market: Opportunities and Threats from a Client Perspective 2016-2026
  • 10.3. Important Aspects of the Outsourcing Decision
    • 10.3.1. What Factors Will Influence CMO Selection?
    • 10.3.2. CMO-Pharma Partnering Models
    • 10.3.3. Strategic Partnering
    • 10.3.4. Selecting a Local CMO vs. Offshoring
    • 10.3.5. CMOs in Emerging Markets
    • 10.3.6. Good Communication is Vital for Success
    • 10.3.7. Ensuring Protection in Intellectual Property and Tech Transfer
    • 10.3.8. Regulatory Compliance is a Key Deciding Factor for Pharma Clients
      • 10.3.8.1. Regulatory Bodies and Outsourcing
      • 10.3.8.2. Quality Agreement
      • 10.3.8.3. Global Harmonisation Will Improve Compliance
  • 10.4. Trends in Outsourcing Partnerships 2016-2026
    • 10.4.1. Big Pharma and Outsourced Manufacturing
    • 10.4.2. Small and Virtual Pharma Companies
    • 10.4.3. How Will Biotech Funding Impact the Pharma Contract Manufacturing Industry to 2026?

11. Research Interviews

  • 11.1. Interview with Gordon Bates, SVP Business Unit Head, Chemical and Microbial Manufacturing, Lonza Pharma & Biotech
    • 11.1.1. Lonza's Pharmaceutical Contract Manufacturing Capabilities and Experience
    • 11.1.2. Upcoming Trends in Drug Development that Will Affect the Pharmaceutical Contract Manufacturing Industry
    • 11.1.3. The Potential of the Emerging Marketplace
    • 11.1.4. Outlook on Qualities Needed For CMO Success
    • 11.1.5. Industry Trends: Changes in the Next Ten Years
  • 11.2. Interview with Dr Michael Quirmbach, VP, Global Sales and Marketing, CordenPharma International
    • 11.2.1. The Range of CDMO Services Available at CordenPharma
    • 11.2.2. CordenPharma's Systematic Approach Navigates the Challenges of HPAPI Manufacturing
    • 11.2.3. Future Trends in the Developed and Emerging Markets for Contract Manufacturing
    • 11.2.4. Certain Manufacturing Sectors are Primed for Growth While Others Decline
    • 11.2.5. Factors for CDMO Success in the Contract Manufacturing Market

12. Conclusions

  • 12.1. The World Pharmaceutical Contract Manufacturing Market
  • 12.2. Outlook for the Market to 2026
    • 12.2.1. Rising Demand for High Value Services 2016-2026
    • 12.2.2. Demand Will Be Highest Among Developed-Market Clients
  • 12.3. Which New Technologies Will Stimulate Demand to 2026?

List of Tables

  • Table 1.1: Pharmaceutical Contract Manufacturing Market: Overall Market and Revenue Forecasts by Sector ($bn), 2015-2026
  • Table 1.2: Currency Exchange Rates
  • Table 3.1: Pharma Contract Manufacturing World Market Revenue ($bn), Annual Growth (%), CAGR (%), 2012-2014
  • Table 3.2: Pharma Contract Manufacturing Market: Revenue ($bn) and Market Share (%) by Sector, 2014
  • Table 3.3: Pharmaceutical Contract Manufacturing Market: Overall Market Forecasts by Sector, Revenue ($bn), Annual Growth (%), CAGR (%), 2015-2026
  • Table 3.4: Pharma Contract Manufacturing Market: Submarket Shares (%), 2014-2020
  • Table 3.5: Pharma Contract Manufacturing Market: Submarket Shares (%), 2021-2026
  • Table 3.6: Other Services Submarket Forecast, Revenue ($bn), Annual Growth (%), CAGR (%), 2015-2026
  • Table 4.1: Contract API Manufacturing Submarket Revenue ($bn), Annual Growth (%), CAGR (%), 2012-2014
  • Table 4.2: Contract API Manufacturing Submarket: Revenue ($bn) and Submarket Share (%) by Sector, 2014
  • Table 4.3: Contract API Manufacturing Submarket: Overall Submarket Forecasts by Sector, Revenue ($bn), Annual Growth (%), CAGR (%), 2015-2026
  • Table 4.4: Contract API Manufacturing Submarket Shares (%), 2014-2020
  • Table 4.5: Contract API Manufacturing Submarket Shares (%), 2021-2026
  • Table 4.6: Contract API Manufacturing Submarket: Drivers and Restraints, 2016-2026
  • Table 4.7: Contract Generic API Manufacturing Submarket Forecast, Revenue ($bn), Annual Growth (%), CAGR (%), 2015-2026
  • Table 4.8: Contract Generic API Manufacturing Submarket: Drivers and Restraints, 2016-2026
  • Table 4.9: Contract HPAPI Manufacturing Submarket Forecast, Revenue ($bn), Annual Growth (%), CAGR (%), 2015-2026
  • Table 4.10: Contract HPAPI Manufacturing Submarket: Drivers and Restraints, 2016-2026
  • Table 5.1: Contract FDF Manufacturing Submarket Revenue ($bn), Annual Growth (%), 2012-2014
  • Table 5.2: Contract FDF Manufacturing Submarket: Revenue ($bn) and Submarket Share (%) by Sector, 2014
  • Table 5.3: Contract FDF Manufacturing Submarket: Overall Submarket Forecasts by Sector, Revenue ($bn), Annual Growth (%), CAGR (%), 2015-2026
  • Table 5.4: Contract FDF Manufacturing Submarket: Segment Shares (%), 2014-2020
  • Table 5.5: Contract FDF Manufacturing Submarket: Segment Shares (%), 2021-2026
  • Table 5.6: Contract FDF Manufacturing Submarket: Drivers and Restraints, 2016-2026
  • Table 5.7: Contract Solid Dosage Manufacturing Submarket Forecast, Revenue ($bn), Annual Growth (%), CAGR (%) 2015-2026
  • Table 5.8: Contract Solid Dosage Manufacturing Submarket: Drivers and Restraints, 2016-2026
  • Table 5.9: Contract Injectable Dosage Manufacturing Submarket Forecast, Revenue ($bn), Annual Growth (%), CAGR (%) 2015-2026
  • Table 5.10: Contract Injectable Dosage Manufacturing Submarket: Drivers and Restraints, 2016-2026
  • Table 5.11: Selected ADCs in Development, 2016
  • Table 5.12: Selected CMOs Investing in ADC Manufacturing Capacity, 2015
  • Table 6.1: Pharma Contract Manufacturing Market: Revenues ($bn) and Market Shares (%) by Region, 2014
  • Table 6.2: Pharma Contract Manufacturing Market: Regional Forecasts, Revenue ($bn), Annual Growth (%), CAGR (%), 2015-2026
  • Table 6.3: Pharmaceutical Contract Manufacturing Market: Developed-Market Shares (%), 2014-2020
  • Table 6.4: Pharmaceutical Contract Manufacturing Market: Developed-Market Shares (%), 2021-2026
  • Table 6.5: GDUFA: Annual Fees for Domestic and Foreign Manufacturing Sites, 2015-2016
  • Table 6.6: US Pharma Contract Manufacturing: Market Forecast, Revenue ($bn), Annual Growth (%), CAGR (%), 2015-2026
  • Table 6.7: EU Pharma Contract Manufacturing Market: Revenue ($bn) and Market Share (%) by Leading Country, 2014
  • Table 6.8: EU Pharma Contract Manufacturing Market: Revenue ($bn) and Market Share (%) by Leading Country, 2015
  • Table 6.9: EU5 Pharma Contract Manufacturing Market: National Market Forecasts, Revenue ($bn), Annual Growth (%), CAGR (%), 2015-2026
  • Table 6.10: German Pharma Contract Manufacturing: Market Forecast, Revenue ($bn), Annual Growth (%), CAGR (%), 2015-2026
  • Table 6.11: Selected French Manufacturing Site Acquisitions, 2009-2013
  • Table 6.12: French Pharma Contract Manufacturing: Market Forecast, Revenue ($bn), Annual Growth (%), CAGR (%), 2015-2026
  • Table 6.13: Italian Pharma Contract Manufacturing: Market Forecast, Revenue ($bn), Annual Growth (%), CAGR (%), 2015-2026
  • Table 6.14: Spanish Pharma Contract Manufacturing: Market Forecast, Revenue ($bn), Annual Growth (%), CAGR (%), 2015-2026
  • Table 6.15: UK Pharma Contract Manufacturing: Market Forecast, Revenue ($bn), Annual Growth (%), CAGR (%), 2015-2026
  • Table 6.16: Japanese Pharma Contract Manufacturing: Market Forecast, Revenue ($bn), Annual Growth (%), CAGR (%), 2015-2026
  • Table 7.1: Pharma Contract Manufacturing Market: Emerging Market Revenue ($bn) and Market Share (%) by Top Country, 2014
  • Table 7.2: Pharma Contract Manufacturing Market: Leading Emerging Market Forecasts ($bn), Annual Growth (%), CAGR (%), 2015-2026
  • Table 7.3: Pharma Contract Manufacturing Market: Emerging-Market Shares (%), 2014-2020
  • Table 7.4: Pharma Contract Manufacturing Market: Emerging-Market Shares (%), 2021-2026
  • Table 7.5: Chinese Pharma Contract Manufacturing: Market Forecast, Revenue ($bn), Annual Growth (%), CAGR (%), 2015-2026
  • Table 7.6: Indian Pharma Contract Manufacturing: Market Forecast, Revenue ($bn), Annual Growth (%), CAGR (%), 2015-2026
  • Table 7.7: Brazilian Pharma Contract Manufacturing: Market Forecast, Revenue ($bn), Annual Growth (%), CAGR (%), 2015-2026
  • Table 7.8: Russian Pharma Contract Manufacturing: Market Forecast, Revenue ($bn), Annual Growth (%), CAGR (%), 2015-2026
  • Table 7.9: South Korean Pharma Contract Manufacturing: Market Forecast, Revenue ($bn), Annual Growth (%), CAGR (%), 2015-2026
  • Table 8.1: Pharma Contract Manufacturing Market: Revenue ($bn) and Market Share (%) by Top Company, 2014
  • Table 8.2: Catalent: Revenue ($bn), Annual Growth (%), CAGR (%), 2010-2015
  • Table 8.3: Lonza Custom Manufacturing: Revenue ($bn), Annual Growth (%), CAGR (%), 2009-2014
  • Table 8.4: Lonza Custom Manufacturing: Revenue ($bn), Annual Growth (%), H1 2014-H1 2015
  • Table 8.5: DSP: Pharmaceutical Biotech Manufacturing Revenue ($bn), Annual Growth (%), CAGR (%), 2011-2014
  • Table 8.6: DPx and DSP: Q3 Revenue ($bn), 2014-2015
  • Table 8.7: Teva: Revenue ($bn), Annual Growth (%), CAGR (%), 2009-2014
  • Table 8.8: Teva API Revenue ($bn), Annual Growth (%), Q3 2014-Q3 2015
  • Table 8.9: Boehringer Ingelheim BioXcellence: Revenue ($bn), Annual Growth (%), CAGR (%), 2010-2014
  • Table 8.10: Famar: Revenue ($bn), Annual Growth (%), CAGR (%), 2011-2014
  • Table 9.1: Pharma Contract Manufacturing Market Strengths and Weaknesses: CMO Perspective, 2016-2026
  • Table 9.2: Pharma Contract Manufacturing Market Opportunities and Threats: CMO Perspective, 2016-2026
  • Table 9.3: Pharma Contract Manufacturing Market: STEP Analysis, 2016-2026
  • Table 9.4: Selected Lyophilisation Service Providers, 2015
  • Table 9.5: Lyophilisation vs. Spray Drying: A Comparison, 2016
  • Table 9.6: Selected Orphan Drug Prices, 2014
  • Table 9.7: Selected Biological Manufacturing Expansion, 2011-2016
  • Table 9.8: Selected EU-Approved Biosimilars: Manufacturers and Companies, 2016
  • Table 9.9: Selected CMOs Growing Faster than the Market, 2007-2012
  • Table 9.10: Regional Market Expansion, 2010-2016
  • Table 10.1: Pharma Contract Manufacturing Market Strengths and Weaknesses: Client Perspective, 2016-2026
  • Table 10.2: Pharma Contract Manufacturing Market Opportunities and Threats: Client Perspective, 2016-2026
  • Table 10.3: Benefits and Risks to Outsourcing Pharma Manufacturing, 2016
  • Table 10.4: ICH Guidelines: Key Facts and Adoption, 2000-2014
  • Table 12.1: Pharma Contract Manufacturing Market: Revenue ($bn), CAGR (%), and Market Share (%) by Sector, 2014, 2020 and 2026
  • Table 12.2: Pharma Contract Manufacturing Market: Revenue ($bn), CAGR (%), and Market Share (%) by Region, 2014, 2020 and 2026

List of Figures

  • Figure 1.1: Global Pharmaceutical Contract Manufacturing Market Segmentation Overview, 2016
  • Figure 2.1: Selected Services Offered by CMOs, 2016
  • Figure 2.2: Major Trends Affecting Pharma Contract Manufacturing Revenue Growth, 2016-2026
  • Figure 3.1: Pharmaceutical Contract Manufacturing Market Revenue ($bn), 2012-2014
  • Figure 3.2: Pharma Contract Manufacturing: Market Share (%) by Sector, 2014
  • Figure 3.3: Pharmaceutical Contract Manufacturing Market: Overall Market Forecast, Revenue ($bn), 2015-2026
  • Figure 3.4: Pharma Contract Manufacturing Market: Submarket Shares (%), 2020
  • Figure 3.5: Pharma Contract Manufacturing Market: Submarket Shares (%), 2026
  • Figure 3.6: Pharma Contract Manufacturing Market: Drivers, 2016-2026
  • Figure 3.7: Pharma Contract Manufacturing Market: Restraints, 2016-2026
  • Figure 3.8: Other Services Submarket Forecast, Revenue ($bn), 2015-2026
  • Figure 4.1: Contract API Manufacturing Submarket Revenue ($bn), 2012-2014
  • Figure 4.2: Contract API Manufacturing Submarket: Segment Shares (%) by Sector, 2014
  • Figure 4.3: Contract API Manufacturing Submarket Forecast, Revenue ($bn), 2015-2026
  • Figure 4.4: Contract API Manufacturing Submarket: Segment Shares (%), 2020
  • Figure 4.5: Contract API Manufacturing Submarket: Segment Shares (%), 2026
  • Figure 4.6: Contract Generic API Manufacturing Submarket Forecast, Revenue ($bn), 2015-2026
  • Figure 4.7: Contract HPAPI Manufacturing Submarket Forecast, Revenue ($bn), 2015-2026
  • Figure 5.1: Contract FDF Manufacturing Submarket Revenue ($bn), 2012-2014
  • Figure 5.2: Contract FDF Manufacturing Submarket: Segment Shares (%) by Sector, 2014
  • Figure 5.3: Contract FDF Manufacturing Submarket Forecast, Revenue ($bn), 2015-2026
  • Figure 5.4: Contract FDF Manufacturing Submarket: Segment Shares (%), 2020
  • Figure 5.5: Contract FDF Manufacturing Submarket: Segment Shares (%), 2026
  • Figure 5.6: Contract Solid Dosage Manufacturing Submarket Forecast ($bn), 2015-2026
  • Figure 5.7: Contract Injectable Dosage Manufacturing Submarket Forecast, Revenue ($bn), 2015-2026
  • Figure 6.1: Pharma Contract Manufacturing Market: Share (%) by Region, 2014
  • Figure 6.2: Pharmaceutical Contract Manufacturing Market: Share (%) by Region, 2020
  • Figure 6.3: Pharmaceutical Contract Manufacturing Market: Share (%) by Region, 2026
  • Figure 6.4: US Pharma Contract Manufacturing: Market Forecast, Revenue ($bn), 2015-2026
  • Figure 6.5: EU5 Pharma Contract Manufacturing Market: Share (%) by Country, 2014
  • Figure 6.6: EU5 Pharma Contract Manufacturing Market: Share (%) by Country, 2015
  • Figure 6.7: EU5 Pharma Contract Manufacturing Market: Share (%) by Country, 2020
  • Figure 6.8: EU5 Pharma Contract Manufacturing Market: Share (%) by Country, 2026
  • Figure 6.9: EU5 Pharma Contract Manufacturing Market: National Market Forecast, Revenue ($bn), 2015-2026
  • Figure 6.10: German Pharma Contract Manufacturing: Market Forecast, Revenue ($bn), 2015-2026
  • Figure 6.11: French Pharma Contract Manufacturing: Market Forecast, Revenue ($bn), 2015-2026
  • Figure 6.12: Italian Pharma Contract Manufacturing: Market Forecast, Revenue ($bn), 2015-2026
  • Figure 6.13: Spanish Pharma Contract Manufacturing: Market Forecast, Revenue ($bn), 2015-2026
  • Figure 6.14: UK Pharma Contract Manufacturing: Market Forecast, Revenue ($bn), 2015-2026
  • Figure 6.15: Japanese Pharma Contract Manufacturing: Market Forecast, Revenue ($bn), 2015-2026
  • Figure 7.1: Pharma Contract Manufacturing Market: Emerging Market Share (%) by Top Country, 2014
  • Figure 7.2: Pharma Contract Manufacturing Market: Emerging Market Share (%) by Top Country, 2020
  • Figure 7.3: Pharma Contract Manufacturing Market: Emerging Market Share (%) by Top Country, 2026
  • Figure 7.4: Pharma Contract Manufacturing Market: Emerging Market Share (%) by Top Country, 2014, 2020 and 2026
  • Figure 7.5: Chinese Pharma Contract Manufacturing: Market Forecast, Revenue ($bn), 2015-2026
  • Figure 7.6: Indian Pharma Contract Manufacturing: Market Forecast, Revenue ($bn), 2015-2026
  • Figure 7.7: Brazilian Pharma Contract Manufacturing: Market Forecast, Revenue ($bn), 2015-2026
  • Figure 7.8: Russian Pharma Contract Manufacturing: Market Forecast, Revenue ($bn), 2015-2026
  • Figure 7.9: South Korean Pharma Contract Manufacturing: Market Forecast, Revenue ($bn), 2015-2026
  • Figure 8.1: Pharma Contract Manufacturing: Market Share (%) by Top Company, 2014
  • Figure 8.2: Catalent: Revenue ($bn), 2010-2015
  • Figure 8.3: Lonza Custom Manufacturing: Revenue ($bn), 2009-2014
  • Figure 8.4: DSP: Pharmaceutical Biotech Manufacturing Revenue ($bn), 2011-2014
  • Figure 8.5: Teva: Revenue ($bn), 2009-2014
  • Figure 8.6: Boehringer Ingelheim BioXcellence: Revenue ($bn), 2010-2014
  • Figure 8.7: Famar: Revenue ($bn), 2011-2014
  • Figure 10.1: Overview of Approved ICH Manufacturing Guidelines, 2016
  • Figure 12.1: Pharma Contract Manufacturing Market: Revenue ($bn) by Sector, 2014, 2020 and 2026
  • Figure 12.2: Pharma Contract Manufacturing Market: Revenue ($bn) by Region, 2014, 2020 and 2026

Companies Listed

  • AbbVie
  • Actavis
  • ADC Biotechnology
  • Aegerion Pharmaceuticals
  • Aenova Group
  • Aesica Pharma
  • Agência Nacional de Vigilância Sanitária (ANVISA)
  • Agensys
  • Agila Specialties
  • Ajinomoto Althea Inc
  • Alexion Pharmaceuticals
  • Almac Group
  • Althea Technologies
  • AMRI (Albany Molecular Research Inc)
  • API Corporation (APIC)
  • Asociación Española de Fabricantes de Productos de Química Fina (AFAQUIM)
  • Aspen Pharmacare
  • Associação Brasileira da Indústria Farmoquímica e de Insumos Farmacêuticos (ABIQUIFI)
  • Association of British Pharmaceutical Industry (ABPI)
  • Astellas
  • AstraZeneca
  • Banner Life Sciences
  • Banner Pharmacaps
  • Baring Private Equity Asia
  • Bausch & Lomb
  • Bayer Healthcare
  • Ben Venue Laboratories
  • Bend Research
  • Biogen Idec
  • BioIndustry Association (BIA)
  • Biotest
  • Blackstone Group
  • Boehringer Ingelheim
  • Boehringer Ingelheim BioXcellence
  • Bristol-Myers Squibb Company
  • Bushu Pharmaceuticals
  • Cambrex
  • Cambridge Major Laboratories
  • Catalent Pharma Solutions
  • Cedarburg Hauser
  • Cell Therapy Catapult
  • Celldex Therapeutics
  • Celltrion
  • Cenexi
  • Central Drugs Standard Control Organization (CDSCO)
  • Chemisch-Pharmazeutisches Laboratorium Ravensburg
  • Chemtrix
  • China FDA (CFDA)
  • Cipla
  • Cook Pharmica
  • CordenPharma
  • CTC Bio
  • Daito Pharmaceutical
  • Delpharm
  • Department of Health and Family Welfare
  • Development and Reform Commission (NDRC)
  • Dishman Pharmaceuticals
  • DPx Fine Chemicals
  • DPx Holdings B.V.
  • Dr. Reddy's Laboratories
  • DSP (DSM Sinochem Pharmaceuticals)
  • Eisai
  • Eli Lilly
  • Esteve Quimica
  • European Commission
  • European Medicines Agency (EMA)
  • Euticals
  • Evonik Degussa
  • Famar
  • Fareva
  • Food and Drug Administration (US FDA)
  • FUJIFILM Diosynth Biotechnologies,
  • Gallus Biopharmaceutical, LLC.
  • G-CON
  • GEA Pharma-Systems
  • Genentech
  • GlaxoSmithKline (GSK)
  • Granules India
  • Haupt Pharma
  • Hexal
  • Hospira
  • Hospira One2One
  • ImmunoGen
  • Immunomedics
  • Indian Drug Manufacturer's Association (IDMA)
  • Indian Pharmaceutical Alliance
  • Innovent Biologics
  • International Society of Pharmaceutical Engineering (IPSE)
  • IRIX Pharmaceuticals
  • Janssen
  • JK Pharmaceutical
  • Johnson & Johnson
  • Knowledge Transfer Network (KTN)
  • Korea Food and Drug Administration (KFDA)
  • Korea Pharmaceutical Manufacturer's Association (KPMA)
  • Lonza
  • Lupin
  • Marinopoulos Group
  • Matrix Laboratories
  • Medice
  • Medichem
  • Medicines and Healthcare Products Regulatory Agency (MHRA)
  • Medicines Manufacturing Industry Partnership (MMIP)
  • Merck & Co.
  • Micron Technologies
  • Millennium
  • Ministry of Health (MOH)
  • Ministry of Health, Labor and Welfare (MHLW)
  • Ministry of Industry and Information Technology (MIIT)
  • Mitsui & Co
  • Momenta Pharmaceuticals
  • Mylan
  • Neuland Laboratories
  • NICE Insight
  • NPS Pharmaceuticals
  • Nycomed
  • Orchid Chemicals & Pharmaceuticals
  • Oxford Biomedica
  • Patheon
  • Patheon Biologics
  • Pfizer
  • Pharmaceutical and Medical Devices Agency (PMDA)
  • Pharmapak Technologies
  • Piramal Pharma Solutions
  • Progenics
  • Quintiles
  • Recepta Biopharma
  • Recipharm
  • Redwood Bioscience
  • Rentschler Biotechnologie
  • Roche
  • Royal DSM
  • SAFC
  • SafeBridge
  • Samsung Bioepis
  • Samsung BioLogics
  • Sandoz
  • Sanofi
  • Seattle Genetics
  • Shandong Xinhua
  • ShangPharma
  • Shire
  • Siegfried AG
  • Sigmar Italia
  • SMS Pharmaceuticals
  • Solvias AG
  • Speedel
  • Stada
  • Stem CentRx
  • Stevenage Bioscience Catalyst
  • Takeda
  • Temmler Group
  • Teva API
  • Thermo Fisher Scientific
  • UMN Pharma
  • UNIGEN
  • Valeant Pharmaceuticals
  • Valerion Therapeutics, LLC.
  • Vetter Pharma-Fertigung GmbH
  • Vivante GMP Solutions
  • West Pharmaceutical Services
  • World Health Organization (WHO)
  • WuXi PharmaTech
  • Zhangjiang Biotech & Pharmaceutical Base Company
  • Zhejiang Jiang Yuan Tang Biotechnology
Back to Top